3 / 10
Page 13
Notes:
J Med Oncl Ther 2017 | Volume 2 Issue 4
allied
academies
Oncology and Biomarkers Summit
November 27-28, 2017 | Atlanta, USA
Annual Congress on
O
ne of themost exciting strategies that has recently gained
traction for treatment of cancer is to target metabolic
processes. Although metabolic drugs that work in theory
have been identified, the glycolytic status of the tumors
often makes these approaches ineffective. Recent work from
the Rosner laboratory has identified a transcription factor
that controls the respiration status of triple-negative breast
cancer (TNBC), the most aggressive subtype of breast cancer.
Therapeutic removal of this protein promotes sensitivity
to agents that target oxidative phosphorylation such as
metformin. Bioinformatic analyses of patient data also
suggests that use of this transcription factor in conjunction
with genes involved in oxidative phosphorylation can serve
as biomarkers to predict therapeutic response to such
treatments in not only breast cancer but across multiple
cancer types. These findings provide a conceptual framework
for cancer therapy development and can be leveraged in
conjunction with other complementary treatments for both
patient selection and long-term treatment.
Speaker Biography
Marsha Rich Rosner has earned her BA in Biochemistry from Harvard University
and her PhD in Biochemistry from MIT. In 1982, she became an Assistant Professor
in the Dept. of Applied Biological Sciences at MIT. She has joined the University of
Chicago faculty as an Associate Professor in 1987 and was promoted to Full Professor
in 1994. She was the Founder and First Chair of the Committee on Cancer Biology,
a degree-granting graduate program leading to the PhD in Cancer Biology. She was
appointed the Charles B Huggins Professor and later became the Chair of the Ben May
Department for Cancer Research for 13 years. She is currently a Fellow of the Institute
for Molecular Engineering and the Institute for Genomics and Systems Biology. She has
received several honors including election as a Fellow of the American Association for
the Advancement of Science (AAAS) in 2011.
e:
m-rosner@uchicago.eduMarsha Rich Rosner
University of Chicago, USA
Rewiring metabolic and redox networks in cancer as a novel diagnostic and
therapeutic strategy